Online citations, reference lists, and bibliographies.
← Back to Search

Cancer Immunotherapy Comes Of Age

I. Mellman, G. Coukos, G. Dranoff
Published 2011 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
Activating the immune system for therapeutic benefit in cancer has long been a goal in immunology and oncology. After decades of disappointment, the tide has finally changed due to the success of recent proof-of-concept clinical trials. Most notable has been the ability of the anti-CTLA4 antibody, ipilimumab, to achieve a significant increase in survival for patients with metastatic melanoma, for which conventional therapies have failed. In the context of advances in the understanding of how tolerance, immunity and immunosuppression regulate antitumour immune responses together with the advent of targeted therapies, these successes suggest that active immunotherapy represents a path to obtain a durable and long-lasting response in cancer patients.
This paper references
10.1016/S1074-7613(00)80089-8
Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor.
H. Nishimura (1999)
10.1172/JCI39991
Anticancer immunochemotherapy using adjuvants with direct cytotoxic effects.
L. Zitvogel (2009)
10.1056/NEJMoa0800251
Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1.
N. Hunder (2008)
10.1080/10428190902943077
Immunotherapy of lymphoma and leukemia with T-cell engaging BiTE antibody blinatumomab
Dirk Nagorsen (2009)
10.1073/pnas.0611533104
Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer
J. Hamanishi (2007)
10.1038/nri1457
Ido expression by dendritic cells: tolerance and tryptophan catabolism
A. Mellor (2004)
10.1158/0008-5472.CAN-07-3095
Epitope landscape in breast and colorectal cancer.
N. Segal (2008)
10.1200/JCO.2000.18.23.3894
Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells.
E. Small (2000)
10.1016/S0952-7915(98)80228-8
The role of CD4+ T cell responses in antitumor immunity.
D. Pardoll (1998)
10.1200/JCO.2008.16.5449
Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens.
M. Dudley (2008)
A recent and clinically impressive attempt at adoptive T-cell therapy using genetically altered, patient-derived T cells
10.1200/JCO.2001.19.9.2370
High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801.
J. Kirkwood (2001)
[Immunology of melanoma].
R. Vanwijck (1974)
10.1126/SCIENCE.1076514
Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes
M. Dudley (2002)
10.1016/J.YSUR.2011.09.017
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
T. Eberlein (2012)
10.1146/ANNUREV.IMMUNOL.21.120601.141135
Does the immune system see tumors as foreign or self?
D. Pardoll (2003)
10.1073/pnas.0603107103
OX40 ligand shuts down IL-10-producing regulatory T cells
T. Ito (2006)
10.1097/00002371-200205000-00007
A Phase I Study of Nonmyeloablative Chemotherapy and Adoptive Transfer of Autologous Tumor Antigen-Specific T Lymphocytes in Patients With Metastatic Melanoma
M. Dudley (2002)
10.1097/CJI.0b013e318156e47e
Ipilimumab (Anti-CTLA4 Antibody) Causes Regression of Metastatic Renal Cell Cancer Associated With Enteritis and Hypophysitis
J. Yang (2007)
10.1007/s00262-005-0092-8
CD4(+)CD25high regulatory T cells increase with tumor stage in patients with gastric and esophageal cancers
K. Kono (2005)
10.1158/1078-0432.CCR-08-1825
Anti–Programmed Death-1 Synergizes with Granulocyte Macrophage Colony-Stimulating Factor–Secreting Tumor Cell Immunotherapy Providing Therapeutic Benefit to Mice with Established Tumors
B. Li (2009)
10.1126/SCIENCE.291.5502.319
Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice.
H. Nishimura (2001)
10.1038/mt.2009.210
Chimeric antigen receptors combining 4-1BB and CD28 signaling domains augment PI3kinase/AKT/Bcl-XL activation and CD8+ T cell-mediated tumor eradication.
X. Zhong (2010)
10.1084/jem.20100643
Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity
Kaori Sakuishi (2010)
10.1111/j.1442-2042.2010.02678.x
Bacillus Calmette–Guérin treatment of non‐muscle invasive bladder cancer
R. Sylvester (2011)
10.1146/annurev.immunol.021908.132544
Immune therapy for cancer.
M. Dougan (2009)
10.1038/nm1093
Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival
T. Curiel (2004)
10.1038/nature10169
Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and Treg cells
A. Facciabene (2011)
10.1084/jem.20090746
Feedback control of regulatory T cell homeostasis by dendritic cells in vivo
G. Darrasse-Jèze (2009)
10.1038/sj.bmt.1705898
Donor leukocyte infusions for the treatment of relapsed acute leukemia after allogeneic stem cell transplantation
A. Loren (2008)
10.1182/BLOOD-2007-02-074716
NK-cell activation and antibody-dependent cellular cytotoxicity induced by rituximab-coated target cells is inhibited by the C3b component of complement.
Siao-Yi Wang (2008)
10.1002/ijc.24597
Immunization with a P53 synthetic long peptide vaccine induces P53‐specific immune responses in ovarian cancer patients, a phase II trial
N. Leffers (2009)
Whole-cell vaccines: A failure or a success waiting to happen?
J. Copier (2010)
Toll - like receptors and their crosstalk with other innate receptors in infection and
T Kawai (2011)
10.1038/nri2326
Inhibitory B7-family molecules in the tumour microenvironment
W. Zou (2008)
10.1182/blood-2008-09-179143
Potent antitumor activity of the anti-CD19 auristatin antibody drug conjugate hBU12-vcMMAE against rituximab-sensitive and -resistant lymphomas.
H. Gerber (2009)
10.4049/jimmunol.0900632
Binding of Submaximal C1q Promotes Complement-Dependent Cytotoxicity (CDC) of B Cells Opsonized with Anti-CD20 mAbs Ofatumumab (OFA) or Rituximab (RTX): Considerably Higher Levels of CDC Are Induced by OFA than by RTX1
Andrew W. Pawluczkowycz (2009)
10.1038/nm0902-1039c
Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
H. Dong (2002)
10.1007/s00281-011-0247-y
Prognostic significance of autoimmunity during treatment of melanoma with interferon
M. Krauze (2011)
10.1056/NEJMoa0810097
Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia.
G. Kenter (2009)
10.1126/science.1160062
CTLA-4 Control over Foxp3+ Regulatory T Cell Function
K. Wing (2008)
10.1056/NEJMoa1003466
Improved survival with ipilimumab in patients with metastatic melanoma.
F. S. Hodi (2010)
10.1126/science.1129139
Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome
J. Galon (2006)
10.1146/ANNUREV.IMMUNOL.24.021605.090733
Human T cell responses against melanoma.
T. Boon (2006)
mechanisms of action and resistance
R. Nahta (2006)
10.1038/nm1100
Cancer immunotherapy: moving beyond current vaccines
S. Rosenberg (2004)
10.1053/j.seminhematol.2010.01.011
Rituximab: mechanism of action.
G. Weiner (2010)
10.1016/J.YSUR.2011.09.022
gp100 Peptide Vaccine and Interleukin-2 in Patients with Advanced Melanoma
T. Eberlein (2012)
Programmedcell death 1 ligand 1 and tumor-infiltratingCD81 T lymphocytes are prognostic factors of human ovarian cancer
J Hamanishi (2007)
L.,Kalos,M., Bagg, A.&June,C.H.Chimeric antigenreceptormodified T cells in chronic lymphoid leukemia
D. L. Porter (2011)
10.1200/JCO.2007.25.18_SUPPL.7554
Final results of a multi-center, double-blind, randomized, placebo-controlled phase II study to assess the efficacy of MAGE-A3 immunotherapeutic as adjuvant therapy in stage IB/II non-small cell lung cancer (NSCLC)
J. Vansteenkiste (2007)
10.1158/1078-0432.CCR-07-0374
A Vascular Endothelial Growth Factor Receptor-2 Inhibitor Enhances Antitumor Immunity through an Immune-Based Mechanism
E. A. Manning (2007)
Translational Research Working Group developmental pathway for immune responsemodifiers.Clin.CancerRes.14,5692–5699
Cheever (2008)
10.1097/PPO.0b013e3181eacbc4
Novel Gamma-Chain Cytokines as Candidate Immune Modulators in Immune Therapies for Cancer
Natasha M. Fewkes (2010)
10.1146/ANNUREV.IMMUNOL.22.012703.104538
Cell biology of antigen processing in vitro and in vivo.
E. S. Trombetta (2005)
10.1111/j.1600-065X.2008.00602.x
Tumor‐induced tolerance and immune suppression by myeloid derived suppressor cells
I. Marigo (2008)
a failure or a success waiting to happen? Curr
J. Copier (2010)
rapamycin augments pathogen-specific but not graft-reactive CD81 T cell responses
Ferrer (2010)
10.1200/JCO.2009.25.0597
Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer.
P. Kantoff (2010)
10.1016/j.smim.2008.09.006
Antigens for cancer immunotherapy.
M. Neller (2008)
10.1182/blood-2009-03-211714
Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen.
L. Johnson (2009)
10.1073/PNAS.95.17.10067
CTLA-4 blockade synergizes with tumor-derived granulocyte-macrophage colony-stimulating factor for treatment of an experimental mammary carcinoma.
A. Hurwitz (1998)
10.1084/jem.20101123
IAP inhibitors enhance co-stimulation to promote tumor immunity
M. Dougan (2010)
10.1038/nri2506
Myeloid-derived suppressor cells as regulators of the immune system
D. Gabrilovich (2009)
10.1158/0008-5472.CAN-10-0153
Antiangiogenic agents can increase lymphocyte infiltration into tumor and enhance the effectiveness of adoptive immunotherapy of cancer.
R. Shrimali (2010)
Tumor-infiltrating lymphocytes: apparently good for melanoma patients
A Cipponi (2011)
10.1517/13543784.15.11.1309
Discontinued drugs in 2005: oncology drugs
L. Kelland (2006)
10.1182/BLOOD-2006-04-020057
Anti-CD20 monoclonal antibody with enhanced affinity for CD16 activates NK cells at lower concentrations and more effectively than rituximab.
J. Bowles (2006)
10.1038/nm1523
Calreticulin exposure dictates the immunogenicity of cancer cell death
M. Obeid (2007)
10.1371/journal.pone.0010436
Agonist Anti-GITR Monoclonal Antibody Induces Melanoma Tumor Immunity in Mice by Altering Regulatory T Cell Stability and Intra-Tumor Accumulation
A. Cohen (2010)
10.1126/science.270.5238.985
Lymphoproliferative Disorders with Early Lethality in Mice Deficient in Ctla-4
P. Waterhouse (1995)
10.1084/jem.20090207
IL-17 can promote tumor growth through an IL-6–Stat3 signaling pathway
L. Wang (2009)
10.4049/jimmunol.174.2.688
Negative Regulation of T Cell Homeostasis by Lymphocyte Activation Gene-3 (CD223)1
C. Workman (2005)
proved survival with ipilimumab in patients with metastatic melanoma
FS Hodi (2010)
Epitope landscape inbreast andcolorectal cancer
N. H. Segal (2008)
tolerance and tryptophan catabolism
A. L. Mellor (2004)
10.1158/1078-0432.CCR-08-1102
Leukemia-Associated Antigens Are Critical for the Proliferation of Acute Myeloid Leukemia Cells
J. Greiner (2008)
10.1016/S0952-7915(96)80078-1
Human tumor antigens recognized by T cells.
P. Robbins (1996)
10.1111/j.1365-2893.2010.01313.x
PD‐1/PD‐L1 pathway and T‐cell exhaustion in chronic hepatitis virus infection
T. Watanabe (2010)
10.1200/JCO.2009.23.3494
Timed sequential treatment with cyclophosphamide, doxorubicin, and an allogeneic granulocyte-macrophage colony-stimulating factor-secreting breast tumor vaccine: a chemotherapy dose-ranging factorial study of safety and immune activation.
L. Emens (2009)
10.1007/s00262-006-0225-8
Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients
F. Ghiringhelli (2006)
10.1200/JCO.2011.29.7_SUPPL.331
A phase I study to evaluate safety and antitumor activity of biweekly BMS-936558 (Anti-PD-1, MDX-1106/ONO-4538) in patients with RCC and other advanced refractory malignancies.
D. McDermott (2011)
10.1038/nm1622
Toll-like receptor 4–dependent contribution of the immune system to anticancer chemotherapy and radiotherapy
L. Apetoh (2007)
10.1084/jem.20100466
PD-1 and LAG-3 inhibitory co-receptors act synergistically to prevent autoimmunity in mice
T. Okazaki (2011)
10.1006/CIMM.1996.0301
HLA class I expression on human ovarian carcinoma cells correlates with T-cell infiltration in vivo and T-cell expansion in vitro in low concentrations of recombinant interleukin-2.
S. Kooi (1996)
10.1093/jnci/djq310
Improved Endpoints for Cancer Immunotherapy Trials
A. Hoos (2010)
10.1016/j.immuni.2010.10.007
Designing vaccines based on biology of human dendritic cell subsets.
K. Palucka (2010)
10.1034/j.1600-065X.2002.18815.x
Towards patient‐specific tumor antigen selection for vaccination
Hans-Georg Rammensee (2002)
10.4049/jimmunol.1001176
Cutting Edge: Rapamycin Augments Pathogen-Specific but Not Graft-Reactive CD8+ T Cell Responses
I. Ferrer (2010)
10.1056/NEJMoa1103849
Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia.
D. Porter (2011)
10.1038/nrc1929
Targeting the mechanisms of tumoral immune tolerance with small-molecule inhibitors
A. J. Muller (2006)
10.1056/NEJMOA063842
Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412.
G. Suntharalingam (2006)
10.1038/nm.1882
Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma
M. Pule (2008)
10.1200/JCO.1988.6.5.839
Immunotherapy of patients with advanced cancer using tumor-infiltrating lymphocytes and recombinant interleukin-2: a pilot study.
S. Topalian (1988)
10.1182/BLOOD-2004-04-1559
Human mesenchymal stem cells modulate allogeneic immune cell responses.
S. Aggarwal (2005)
10.1182/BLOOD.V86.4.1261.BLOODJOURNAL8641261
Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: separation of graft-versus-leukemia responses from graft-versus-host disease.
S. Mackinnon (1995)
safety, clinical activity, pharmacodynamics, and immunologic correlates
Brahmer (2010)
10.1056/nejmx120071
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
G. Sonpavde (2011)
10.1089/hum.2010.131
Do CARs need a driver's license? Adoptive cell therapy with chimeric antigen receptor-redirected T cells has caused serious adverse events.
H. Buening (2010)
10.1200/JCO.2010.32.8419
Allogeneic transplantation for lymphoma.
R. Chakraverty (2011)
10.1038/nm.2028
Activation of the NLRP3 inflammasome in dendritic cells induces IL-1β–dependent adaptive immunity against tumors
F. Ghiringhelli (2009)
10.1158/0008-5472.CAN-08-1776
Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate.
Gail D Lewis Phillips (2008)
10.1158/1078-0432.CCR-09-1624
Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
J. Wolchok (2009)
Time-dependent cytotoxic drugs selectively cooperate with IL18 for cancer
I Alagkiozidis (2011)
10.1038/nm1517
Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma
A. Parsa (2007)
Cyclophosphamide, doxorubicin, and paclitaxel enhance the antitumor immune response of granulocyte/macrophage-colony stimulating factor-secreting whole-cell vaccines in HER-2/neu tolerized mice.
J. Machiels (2001)
10.1016/1074-7613(95)90125-6
Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4.
E. Tivol (1995)
10.1016/J.MOLMED.2003.11.003
IDO and tolerance to tumors.
D. Munn (2004)
10.4049/jimmunol.178.3.1505
Effects of Vascular Endothelial Growth Factor on the Lymphocyte-Endothelium Interactions: Identification of Caveolin-1 and Nitric Oxide as Control Points of Endothelial Cell Anergy1
C. Bouzin (2007)
TargetingHER 2positivebreast cancerwith trastuzumabDM 1 , an antibodycytotoxic drug conjugate
G. D. Lewis Phillips (2008)
10.1158/1078-0432.CCR-08-1266
Translational Research Working Group Developmental Pathway for Immune Response Modifiers
M. Cheever (2008)
apparently good for melanoma patients
A. Cipponi (2011)
Anti - PD - 1 and - B 7 – H 1 / PD - L 1 monoclonal antibodies
EF Lipson
10.1053/j.seminoncol.2010.09.013
Signaling through OX40 enhances antitumor immunity.
S. Jensen (2010)
10.1073/pnas.0915174107
PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors
M. Curran (2010)
10.1158/1078-0432.CCR-07-0507
Augmented HER-2–Specific Immunity during Treatment with Trastuzumab and Chemotherapy
C. Taylor (2007)
10.1146/ANNUREV.IMMUNOL.21.120601.141040
Tolerogenic dendritic cells.
R. Steinman (2003)
10.1016/J.IMMUNI.2004.08.010
Role of LAG-3 in regulatory T cells.
C. Huang (2004)
10.1002/0471142905.hg1308s14
Cancer Vaccines
T. Greten (2001)
10.1200/JCO.2008.19.8903
Placebo-controlled phase III trial of patient-specific immunotherapy with mitumprotimut-T and granulocyte-macrophage colony-stimulating factor after rituximab in patients with follicular lymphoma.
A. Freedman (2009)
10.1002/eji.201040630
Dendritic cells in cancer immunotherapy
G. Schuler (2010)
10.1056/NEJMoa1001294
Sipuleucel-T immunotherapy for castration-resistant prostate cancer.
P. Kantoff (2010)
10.1093/jnci/djr246
Opportunities and challenges in the development of experimental drug combinations for cancer.
R. Humphrey (2011)
10.1111/j.1600-065X.2008.00621.x
The promise of 4‐1BB (CD137)‐mediated immunomodulation and the immunotherapy of cancer
D. H. Lynch (2008)
al.A2A adenosine receptorprotects tumors from antitumor T cells
Ohta (2006)
10.1200/JCO.1997.15.11.3363
High-titer HER-2/neu protein-specific antibody can be detected in patients with early-stage breast cancer.
M. Disis (1997)
10.1007/s00262-004-0560-6
A listing of human tumor antigens recognized by T cells: March 2004 update
L. Novellino (2004)
10.1158/1078-0432.CCR-08-1608
Overexpression of PD-L1 Significantly Associates with Tumor Aggressiveness and Postoperative Recurrence in Human Hepatocellular Carcinoma
Q. Gao (2009)
10.1517/14712598.4.4.455
Application of IL-2 and other cytokines in renal cancer
D. McDermott (2004)
The authors summarize the current state of the art use of autologous dendritic cell vaccines
10.1200/JCO.2009.27.2146
Immune regulation of cancer.
M. Disis (2010)
10.1056/NEJM199401133300204
Induction of graft-versus-host disease as immunotherapy for relapsed chronic myeloid leukemia.
D. Porter (1994)
10.1146/annurev.immunol.26.021607.090331
PD-1 and its ligands in tolerance and immunity.
M. Keir (2008)
10.1016/J.IMMUNI.2007.08.015
Disruption of E-cadherin-mediated adhesion induces a functionally distinct pathway of dendritic cell maturation.
Aimin Jiang (2007)
10.1084/JEM.191.3.411
The Induction of Tolerance by Dendritic Cells That Have Captured Apoptotic Cells
R. Steinman (2000)
10.1016/S0092-8674(01)00449-4
Dendritic Cells Specialized and Regulated Antigen Processing Machines
I. Mellman (2001)
A Commotion in the Blood: Life, Death, and the Immune System
S. Hall (1997)
10.1097/PPO.0b013e3181eb336d
Regulatory T Cells: Overcoming Suppression of T-Cell Immunity
T. Golovina (2010)
10.1016/j.cellimm.2009.01.006
Vascular endothelial growth factor-induced chemotaxis and IL-10 from T cells.
J. Shin (2009)
immune-related response criteria
Wolchok (2009)
10.1200/JCO.2009.26.7609
Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates.
J. Brahmer (2010)
10.1007/s00262-011-1026-2
Tumor-infiltrating lymphocytes: apparently good for melanoma patients. But why?
A. Cipponi (2011)
10.1016/j.coi.2008.07.004
Role of KIRs and KIR ligands in hematopoietic transplantation.
A. Velardi (2008)
10.1038/74704
Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets
R. Clynes (2000)
10.1007/s002620000169
A listing of human tumor antigens recognized by T cells
N. Renkvist (2001)
10.1158/0008-5472.CAN-10-2880
Multiple injections of electroporated autologous T cells expressing a chimeric antigen receptor mediate regression of human disseminated tumor.
Y. Zhao (2010)
10.1126/science.271.5256.1734
Enhancement of Antitumor Immunity by CTLA-4 Blockade
D. Leach (1996)
10.1126/science.1203486
Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion
R. Schreiber (2011)
10.1002/cncr.25747
Overall survival and PD‐L1 expression in metastasized malignant melanoma
J. Gadiot (2011)
10.1186/1479-5876-9-77
Time-dependent cytotoxic drugs selectively cooperate with IL-18 for cancer chemo-immunotherapy
Ioannis Alagkiozidis (2010)
moving beyond current vaccines
S. A. Rosenberg (2004)
10.1084/jem.20031435
Mesothelin-specific CD8+ T Cell Responses Provide Evidence of In Vivo Cross-Priming by Antigen-Presenting Cells in Vaccinated Pancreatic Cancer Patients
A. M. Thomas (2004)
GA-101, a third-generation, humanized and glyco-engineered anti-CD20 mAb for the treatment of B-cell lymphoid malignancies.
T. Robak (2009)
10.1056/NEJMOA020177
Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer.
L. Zhang (2003)
10.1146/ANNUREV.IMMUNOL.19.1.565
CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy.
C. A. Chambers (2001)
identification of caveolin-1 and nitric oxide as control points of endothelial cell anergy
C. Bouzin (2007)
10.1073/PNAS.86.24.10024
Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity.
G. Gross (1989)
10.1200/JCO.2010.32.7270
Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival.
M. Topp (2011)
10.1038/nm1699
Endothelin B receptor mediates the endothelial barrier to T cell homing to tumors and disables immune therapy
R. Buckanovich (2008)
10.1073/pnas.0712237105
Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients
F. S. Hodi (2008)
Roleof LAG-3 in regulatoryT cells
Huang (2004)
Polymorphisms in FcgammaRIIIA (CD16) receptor expression are associated with clinical response to rituximab in Waldenström's macroglobulinemia.
S. Treon (2005)
10.1200/JCO.2010.28.15_SUPPL.2506
Safety and antitumor activity of biweekly MDX-1106 (Anti-PD-1, BMS-936558/ONO-4538) in patients with advanced refractory malignancies.
M. Sznol (2010)
10.1002/eji.200939874
Differential subcellular localization of the regulatory T‐cell protein LAG‐3 and the coreceptor CD4
Seng-Ryong Woo (2010)
10.1126/scitranslmed.3002842
T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia
M. Kalos (2011)
Chimeric antigen receptormodified T cells in chronic lymphoid leukemia
D L Porter (2011)
10.1200/JCO.1994.12.7.1475
In vitro predictors of therapeutic response in melanoma patients receiving tumor-infiltrating lymphocytes and interleukin-2.
D. Schwartzentruber (1994)
10.1182/blood-2010-04-281931
Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19.
J. Kochenderfer (2010)
10.1097/PPO.0b013e3181eb3879
Adoptive Cell Therapy: Genetic Modification to Redirect Effector Cell Specificity
R. Morgan (2010)
10.1172/JCI29470
Antibody-enhanced cross-presentation of self antigen breaks T cell tolerance.
Stephanie O. Harbers (2007)
rapamycin augments pathogen-specific but not graft-reactive CD81 T cell responses
Ferrer (2010)
10.1200/JCO.2010.32.2537
Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1.
P. Robbins (2011)
10.1172/JCI31446
Principles of adoptive T cell cancer therapy.
C. June (2007)
10.1056/NEJMoa1104621
Ipilimumab plus dacarbazine for previously untreated metastatic melanoma.
C. Robert (2011)
Guidelines for the evaluationof immune therapyactivity insolid tumors : immunerelated response criteria
J. D. Wolchok (2009)
March 2004 update
L. Novellino (2005)
Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood
S Aggarwal (2005)
10.1016/J.VIROL.2008.11.046
Papillomaviruses in the causation of human cancers — a brief historical account
H. Hausen (2009)
10.1158/1078-0432.CCR-10-0041
Clinical Responses in a Phase II Study Using Adoptive Transfer of Short-term Cultured Tumor Infiltration Lymphocytes in Metastatic Melanoma Patients
M. Besser (2010)
10.1111/j.1365-2893.2009.01172.x
Clearance of hepatitis C in chimpanzees is associated with intrahepatic T‐cell perforin expression during the late acute phase
H. Watanabe (2010)
10.1038/nri727
The B7–CD28 superfamily
A. Sharpe (2002)
10.1200/JCO.2003.05.013
Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma.
W. Weng (2003)
10.1056/NEJMRA043186
Trastuzumab--mechanism of action and use in clinical practice.
C. Hudis (2007)
10.1093/JNCI/86.15.1159
Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2.
S. Rosenberg (1994)
Phase I study of singleagent antiprogrammeddeath1 ( MDX1106 ) in refractory solid tumors : safety , clinical activity , pharmacodynamics , and immunologic correlates
J. R. Brahmer (2010)
A 2 Aadenosine receptorprotects tumors fromantitumorT cells
A. Ohta (2006)
10.1073/pnas.0605251103
A2A adenosine receptor protects tumors from antitumor T cells
A. Ohta (2006)
10.1053/j.seminoncol.2010.09.010
Clinical development of the anti-CTLA-4 antibody tremelimumab.
A. Ribas (2010)
10.1016/J.CANLET.2005.01.041
Herceptin: mechanisms of action and resistance.
R. Nahta (2006)
CD40 Agonists Alter Tumor Stroma and Show Efficacy Against Pancreatic Carcinoma in Mice and Humans
S. Gende (2011)
overcoming suppression of T-cell immunity
T. N. Golovina (2010)
Anti-PD-1 and -B7–H1/PD-L1 monoclonal antibodies, in Gajewski TF, Hodi FS (eds): Targeted Therapeutics in Melanoma
EF Lipson (2011)
The authors summarize the argument for using a different set of criteria to evaluate the efficacy of immunotherapies given the mechanistic differences from conventional anticancer drugs
10.1016/j.immuni.2011.05.006
Toll-like receptors and their crosstalk with other innate receptors in infection and immunity.
T. Kawai (2011)
10.1038/mt.2011.1
CARs on track in the clinic.
D. Kohn (2011)
10.1158/0008-5472.CAN-03-2862
Rituximab-Dependent Cytotoxicity by Natural Killer Cells
S. Dall'ozzo (2004)
10.1056/NEJMoa1002965
Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas.
A. Younes (2010)
10.1073/pnas.1533209100
Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma
G. Phan (2003)
10.1200/JCO.2009.24.3675
Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma.
N. Senzer (2009)
10.1038/nrc2355
Adoptive cell transfer: a clinical path to effective cancer immunotherapy
S. Rosenberg (2008)



This paper is referenced by
Cancer immunotherapy with a gene modified serotype 3 oncolytic virus
Otto Hemminki (2015)
Immunotherapy with immunomodulatory antibody for hepatocellular carcinoma
Liang Huang (2016)
10.1016/B978-0-12-801419-6.00009-4
Chapter 9 – New Targeted Therapies for Brain Metastases from Breast and Lung Cancer and Melanoma
Emmanouil Fokas (2015)
10.1007/s10549-012-2356-2
Prognostic evaluation of the B cell/IL-8 metagene in different intrinsic breast cancer subtypes
L. Hanker (2012)
10.1007/s10549-020-05548-y
Tertiary lymphoid structures and associated plasma cells play an important role in the biology of triple-negative breast cancers
D. Y. B. Seow (2020)
10.5772/INTECHOPEN.80889
Vaccines Developed for Cancer Immunotherapy
Aizong Shen (2018)
10.1007/s12282-016-0682-7
Altered expression of major immune regulatory molecules in peripheral blood immune cells associated with breast cancer
Kosuke Kawaguchi (2016)
10.1080/2162402X.2016.1218105
Natural killer cell recognition of in vivo drug-induced senescent multiple myeloma cells
F. Antonangeli (2016)
10.1586/14760584.2013.845530
Preclinical vaccines against mammary carcinoma
Pier-Luigi Lollini (2013)
10.1016/S1470-2045(15)00554-9
TIME for a successful cancer vaccine in NSCLC?
C. Butts (2016)
10.1634/theoncologist.2018-0167
Antitumor Effect of Nivolumab on Subsequent Chemotherapy for Platinum-Resistant Ovarian Cancer.
Y. Inayama (2018)
10.1002/jgm.2645
When transgenes shape immunity: cancer immune‐gene therapy
C. Bonini (2012)
10.1126/scitranslmed.3006353
Genetic Engineering of Hematopoiesis for Targeted IFN-α Delivery Inhibits Breast Cancer Progression
Giulia Escobar (2014)
10.1016/j.biomaterials.2012.12.031
A liposome-based antigen delivery system using pH-sensitive fusogenic polymers for cancer immunotherapy.
E. Yuba (2013)
10.1038/nrc3498
Plasticity of tumour and immune cells: a source of heterogeneity and a cause for therapy resistance?
M. Hölzel (2013)
10.1155/2013/857519
Immune-Mediated Adverse Events Associated with Ipilimumab CTLA-4 Blockade Therapy: The Underlying Mechanisms and Clinical Management
A. Tarhini (2013)
10.1016/j.coi.2017.04.003
Reenergizing T cell anti-tumor immunity by harnessing immunometabolic checkpoints and machineries.
Ping-Chih Ho (2017)
10.1016/j.addr.2017.06.008
Combinatorial immunotherapy and nanoparticle mediated hyperthermia.
Austin J. Moy (2017)
10.1039/c8bm01403e
A peptide-modified solid lipid nanoparticle formulation of paclitaxel modulates immunity and outperforms dacarbazine in a murine melanoma model.
Indranil Banerjee (2019)
10.1259/bjr.20180164
Adverse effects and radiological manifestations of new immunotherapy agents.
Y. Tang (2018)
10.1016/S1877-1203(16)30128-8
Immunothérapie : les checkpoints
C. Caux (2016)
10.1097/PPO.0000000000000203
Opportunities for Radiosensitization in the Stereotactic Body Radiation Therapy (SBRT) Era.
Everett J. Moding (2016)
10.1016/B978-0-12-374279-7.17012-2
NK Cells in Antitumor Immunity
A. Cerwenka (2016)
10.18632/oncotarget.8784
B7-H3 as a promising target for cytotoxicity T cell in human cancer therapy
J. Ma (2016)
10.1016/j.celrep.2018.02.049
PI3K/Akt Cooperates with Oncogenic Notch by Inducing Nitric Oxide-Dependent Inflammation.
S. Villegas (2018)
10.1039/c8nr01376d
Induction of necrotic cell death and activation of STING in the tumor microenvironment via cationic silica nanoparticles leading to enhanced antitumor immunity.
Myunggi An (2018)
10.1080/17425255.2018.1540588
Turning cold tumors into hot tumors: harnessing the potential of tumor immunity using nanoparticles
A. Rodallec (2018)
10.2217/imt-2020-0063
Investigative therapy for advanced esophageal cancer using the option for combined immunotherapy and chemotherapy.
Huan Wang (2020)
10.1007/978-1-4939-2288-8_9
Ex vivo generation of functional immune cells by mitochondria-targeted photosensitization of cancer cells.
Sean Marrache (2015)
10.1097/PPO.0000000000000162
Tumor-Infiltrating Lymphocyte Therapy: Addressing Prevailing Questions
L. Radvanyi (2015)
10.18632/oncotarget.11274
Discovery of peptide inhibitors targeting human programmed death 1 (PD-1) receptor
Q. Li (2016)
10.3892/ol.2017.6640
New use of microsatellite instability analysis in endometrial cancer
Haruko Kunitomi (2017)
See more
Semantic Scholar Logo Some data provided by SemanticScholar